Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 7/20 | 0.59 |
| ▸ | KDM1A | O60341 | 5/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4719284 | 1.00 | FFAR1 (0.59) | FFAR1KDM1AHRH3KCNH2MAOB | |
| SCHEMBL455245 | 1.00 | FFAR1 (0.59) | FFAR1KDM1AHRH3KCNH2MAOB | |
| SCHEMBL806142 | 1.00 | FFAR1 (0.59) | FFAR1KDM1AHRH3KCNH2MAOB | |
| SCHEMBL455246 | 1.00 | FFAR1 (0.59) | FFAR1KDM1AHRH3KCNH2MAOB | |
| SCHEMBL437376 | 1.00 | FFAR1 (0.59) | FFAR1KDM1AHRH3KCNH2MAOB | |
| SCHEMBL21501045 | 1.00 | FFAR1 (0.59) | FFAR1KDM1AHRH3KCNH2MAOB | |
| SCHEMBL24890441 | 0.84 | KDM1A (0.50) | FFAR1KDM1AHRH3KCNH2MAOB | |
| SCHEMBL799464 | 0.82 | HRH3 (0.49) | FFAR1KDM1AHRH3KCNH2MAOB | |
| SCHEMBL4133964 | 0.82 | KDM1A (0.53) | FFAR1KDM1AHRH3KCNH2MAOB | |
| SCHEMBL4133967 | 0.82 | KDM1A (0.53) | FFAR1KDM1AHRH3KCNH2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4709708-A1 | NOVEL CARBOXAMIDE DERIVATIVES | ANGELINI PHARMA S.P.A. (IT) | 2026-03-18 | — | — | EP | disclosed |
| WO-2025264700-A1 | GIP RECEPTOR AGONIST COMPOUNDS | ELI LILLY AND COMPANY (US) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025106910-A1 | DEGRADER MOLECULES TARGETING ANDROGEN RECEPTOR | FLARE THERAPEUTICS INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| WO-2024233603-A1 | NOVEL CARBOXAMIDE DERIVATIVES | ICAGEN, LLC (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2023284651-A1 | N-(2-AMINOPHENYL)BENZAMIDE COMPOUND AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2023-01-19 | — | — | WO | disclosed |
| US-11021427-B2 | Pd(II)-catalyzed enantioselective C—H arylation of free carboxylic acids | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-06-01 | — | — | US | disclosed |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2019-06-25 | — | — | US | disclosed |
| US-10233178-B2 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | ORYZON GENOMICS, S.A. (ES) | 2019-03-19 | — | — | US | disclosed |
| US-20180127406-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | ORYZON GENOMICS SA (ES) | 2018-05-10 | — | — | US | disclosed |
| US-20120071651-A1 | Processes for Preparing 1,2-Substituted Cyclopropyl Derivatives | ABBOTT LABORATORIES (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071651-A1 | Processes for Preparing 1,2-Substituted Cyclopropyl Derivatives | ABBOTT LABORATORIES (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110201622-A1 | Solid Forms Comprising A Cyclopropyl Amide Derivative | ASTRAZENECA PHARMACEUTICALS LP | 2011-08-18 | — | — | US | disclosed |
| US-20110201622-A1 | Solid Forms Comprising A Cyclopropyl Amide Derivative | ASTRAZENECA PHARMACEUTICALS LP | 2011-08-18 | — | — | US | disclosed |
| US-20110201623-A1 | Crystalline Form Of A Cyclopropyl Benzamide Derivative | ASTRAZENECA PHARMACEUTICALS LP | 2011-08-18 | — | — | US | disclosed |
| US-20110201623-A1 | Crystalline Form Of A Cyclopropyl Benzamide Derivative | ASTRAZENECA PHARMACEUTICALS LP | 2011-08-18 | — | — | US | disclosed |
| US-20110201623-A1 | Crystalline Form Of A Cyclopropyl Benzamide Derivative | ASTRAZENECA PHARMACEUTICALS LP | 2011-08-18 | — | — | US | disclosed |
| US-20100216812-A1 | Cyclopropyl Amide Derivatives | ASTRAZENECA AB (SE) | 2010-08-26 | — | — | US | disclosed |
| US-20100216812-A1 | Cyclopropyl Amide Derivatives | ASTRAZENECA AB (SE) | 2010-08-26 | — | — | US | disclosed |
| US-20100216812-A1 | Cyclopropyl Amide Derivatives | ASTRAZENECA AB (SE) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201622-A1 | Solid Forms Comprising A Cyclopropyl Amide Derivative | SFPQ, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SBDS | FFAR1 2695/4885KDM1A 878/4885HRH3 1977/4885 |
| US-10233178-B2 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | KDM6A, KDM1B, KDM1A | FFAR1 2820/4885KDM1A 3/4885HRH3 730/4885 |
| US-20180127406-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | KDM6A, KDM1B, KDM1A | FFAR1 2820/4885KDM1A 3/4885HRH3 730/4885 |
| US-20100216812-A1 | Cyclopropyl Amide Derivatives | HRH4, HRH2, HRH3 | FFAR1 48/4885KDM1A 760/4885HRH3 3/4885 |
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GCGR | FFAR1 65/4885KDM1A 4614/4885HRH3 600/4885 |
| US-11021427-B2 | Pd(II)-catalyzed enantioselective C—H arylation of free carboxylic acids | PDCD1, PDK3, PDCD1LG2 | FFAR1 119/4885KDM1A 1577/4885HRH3 49/4885 |
| US-20120071651-A1 | Processes for Preparing 1,2-Substituted Cyclopropyl Derivatives | HRH3, HRH4, HRH1 | FFAR1 211/4885KDM1A 1116/4885HRH3 1/4885 |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | FFAR1 3080/4885KDM1A 2/4885HRH3 435/4885 |
| US-20110201623-A1 | Crystalline Form Of A Cyclopropyl Benzamide Derivative | GBA1, BAK1, BBC3 | FFAR1 854/4885KDM1A 2260/4885HRH3 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.